<DOC>
	<DOCNO>NCT01573637</DOCNO>
	<brief_summary>The efficacy raloxifene versus placebo compare six-month period , adjuvant treatment negative symptom schizophrenia group 80 post-menopausal woman . The aim study analyze whether raloxifene effect positive negative symptom schizophrenia , psychopathological symptom general , social neuropsychological functioning , study influence genetic polymorphism treatment response .</brief_summary>
	<brief_title>Raloxifene Adjuvant Treatment Negative Symptoms Schizophrenia Post-menopausal Women</brief_title>
	<detailed_description>Several study find gender-related difference epidemiology , clinical presentation , clinical course response treatment schizophrenic disorder ( 1,2 ) . Findings relate low frequency schizophrenia woman , later onset less severe clinical course ( 3,4 ) , lead appearance `` estrogen hypothesis '' schizophrenia , postulate estrogen protective effect woman susceptible disease ( 5 ) . The estrogen hypothesis relation schizophrenia base several study show estrogen level significantly low schizophrenic woman healthy woman , ( 6 ) outbreak onset disease tend coincide stage menstrual cycle estrogen level lowest ( 7,8 ) . Studies experimental animal show estrogen modulate effect brain dopaminergic system ( 9,10 ) also affect serotoninergic activity ( 11 ) . Estrogens also enhance neuronal regeneration block mechanisms neuronal death ( 12 ) . The discovery estrogen modulatory effect dopaminergic system encourage researcher study therapeutic use estrogen schizophrenic patient . Several double-blind clinical trial show estrogen effective improve psychotic symptom ( 13-15 ) . These last study analyze efficacy estrogens one two month , mainly relation positive symptom , patient acute illness . However , old patient severity negative , rather positive , symptoms seem associate poorer cognitive social function . Moreover , positive symptom tend less severe age , negative symptom tend persist ( 16 ) . Regarding possible use estrogens treat post-menopausal woman schizophrenia , Lindamer et al. , ( 17 ) study psychopathology menopausal patient schizophrenia find patient hormone replacement therapy require low dos antipsychotic drug present less negative symptom , whereas difference find response treatment relation positive symptom . The great frequency later onset schizophrenia woman men seem related drop estrogen level occur menopause . HÃ¤fner et al . ( 19 ) find schizophrenia late onset severe woman men , especially relation negative symptom , result also appear support hypothesis estrogen act protective factor menopause . The use estrogens adjuvant therapy schizophrenia seem promising , although long-term treatment potentially negative effect breast uterine tissue ( 20,21 ) . This reason choose raloxifene study , selective estrogen receptor modulator ( SERM ) act tissue-selective agonist antagonist . Raloxifene first-generation SERM use preventive treatment post-menopausal osteoporosis affect breast ovarian tissue . ( 22 ) . It agonistic effect brain ( 23 ) . Raloxifene seem influence multiple neurotransmission pathway , include seratonin frontal cortex , basal striate ganglion ( 24 ) , area brain commonly affect schizophrenic patient . There evidence raloxifene useful treatment mental disorder post-menopausal woman ( 25,26 ) . Recently , Kulkarni et al . ( 27 ) report preliminary data also seem support role raloxifene schizophrenic patient . Our team conduct 12-week , randomize , double-blind , placebo-controlled clinical trial fund Stanley Foundation , ass value 60 mg raloxifene adjuvant treatment negative symptom , psychotic symptom , post-menopausal woman . In study 33 patient , find woman raloxifene group show great improvement positive negative symptom , also general psychopathological symptom , woman receive antipsychotic medication ( 28 ) . Since part Raloxifene 's mechanism action involve activate estrogenic receptor , study explore possibility polymorphism alfa ( ESR1 ) beta ( ESR2 ) estrogenic receptor gene modify effect treatment raloxifene ( 29-31 ) . Several pharmacogenomic study report single nucleotide polymorphism ( SNPs ) gene , affect raloxifene treatment relation endothelial function ( 29 ) , cholesterol level ( 30 ) bone mineral density ( 31 ) . Nevertheless , study assess whether SNPs ESR1 ESR2 influence raloxifene 's effect brain . Based positive result preliminary study , design longer clinical trial dose raloxifene effective first study . We aim include 6-month placebo-controlled , randomize , double-blind clinical trial large number post-menopausal woman schizophrenia , improve clinical assessment use large battery psychometric test area social functioning neuropsychological performance . Genotypic study conduct 4 SNPs ESR1 ( rs9340799 , rs2234693 , rs1801132 ) ESR2 ( rs1256049 ) gene , control effect patient ' genotype response treatment . DESCRIPTION OF THE TARGET POPULATION The sample include post-menopausal woman diagnose schizophrenia accord DSM-IV-TR criterion . Post-menopause define 1 ) age 45 year minimum one year amenorrhea FSH level higher 20 UI/L 2 ) age 50 year old least one year amenorrhea .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis schizophrenia accord DSMIV TR criterion . 2 . Postmenopausal patient . Postmenopausal define 1 ) age 45 year least one year amenorrhea level FSH 20 UI/L 2 ) age 50 year least one year amenorrhea . 3 . Patients take stable dose antispsychotic medication least 30 day start study . 4 . The presence significant negative symptom ( defined one negative symptom severity 4 PANSS scale ) . 5 . General write informed consent patient legal representative . 6 . For genotypic study , specific informed consent sign patient legal representative require . Exclusion criterion : 1 . A diagnosis substance abuse/dependence previous 6 month . 2 . Mental retardation 3 . A diagnosis major depression ( accord DSMIV TR criterion ) . 4 . Endocrine alteration relate sexual hormone , liver insufficiency include cholestasis , severe renal insufficiency . 5 . History current condition thromboembolism , breast cancer , abnormal uterine bleeding stroke . 6 . Patients hormone replacement therapy . 7 . Known allergy hypersensitivity active ingredient investigational drug , excipients lactose . 8 . To receive treatment another clinical trial . 9 . To present severe concomitant disease researcher 's opinion compromise completion study affect patient 's tolerance treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>negative schizophrenia</keyword>
	<keyword>schizophrenia post-menopausal woman</keyword>
	<keyword>schizophrenia woman</keyword>
	<keyword>ralixifene</keyword>
	<keyword>raloxifen</keyword>
	<keyword>raloxifeno</keyword>
	<keyword>negative symptom schizophrenia</keyword>
	<keyword>negative symptom schizophrenia</keyword>
	<keyword>schizophrenia symptom</keyword>
	<keyword>negative symptom psychosis</keyword>
</DOC>